GARM Clinic conducted the inaugural Klotho Longevity Residency, administering a proprietary Klotho therapy via lipid nanoparticle platform to 22 participants and measuring individualized biomarker responses. The event represents a clinical implementation model that combines direct researcher-patient engagement with supervised biological intervention and biomarker tracking.
Key Points
- Klotho therapy delivered intravenously via lipid nanoparticle platform
- 22 participants with pre- and post-procedure biomarker assessment
- Three leading Klotho researchers engaged directly with patients clinically
Longevity Analysis
Klotho signaling regulates multiple core physiological processes—energy production, circulation, regeneration, and stress response among them—making it a legitimate target for longevity intervention. The residency model demonstrates a shift toward structured, measurable clinical implementation rather than theoretical research. By collecting individualized biomarker data before and after intervention, participants and clinicians gain interpretable feedback on systemic response. This approach acknowledges that longevity work requires both strategic intervention and rigorous tracking of whether the intervention actually changes the biological signals that predict durability and function in aging.
Original published by LT Wire.